- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02143700
Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients (COPD)
Clinical Profile and Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Chronic obstructive pulmonary disease is a pathology with a systemic impact with a progressive evolution that is characterized by the presence of chronic airflow obstruction.
Patients with COPD may have problems with cognitive functioning, either globally or in single cognitive domains, such as information processing, attention and concentration, memory, executive functioning and self-regulation.
Several studies have determined the prevalence of cognitive impairment in COPD compared to healthy control subjects, reaching very high levels, 36% of COPD patients with mild cognitive impairment compared with 12 % non- COPD subjects.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
-
Granada, Espagne, 18071
- Recrutement
- Department of Physical Therapy
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Clinical diagnosis of chronic obstructive pulmonary disease with exacerbation or stable.
- Signed written consent.
- Medical approval for inclusion
Exclusion Criteria:
- Heart disease.
- Neurological patients.
- Severe cognitive impairment in order not to complete the assessment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Stable and exacerbated patients
Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation.
Cognitive assessment of these patients will be performed.
|
Patients are going to be assessed regarding the outcome measures
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Cognitive impairment
Délai: Baseline
|
The cognitive impairment will be measured using the Montreal Cognitive Assessment.
The Montreal Cognitive Assessment is a test designed as a rapid screening instrument for mild cognitive dysfunction.
It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
|
Baseline
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Sleep quality
Délai: Baseline
|
Participants are going to complete the Pittsburgh Quality of Sleep Index.
This is a self-rating questionnaire with seven subscores that result in a global score between 0 and 21.
|
Baseline
|
|
Activity monitoring
Délai: Baseline
|
The accelerometer Armband is going to be used for activity monitoring.
It measures the intensity of the activity during 12 hours.
|
Baseline
|
|
Nutritional state
Délai: Baseline
|
Mini Nutritional Assessment has been designed and validated to provide a single, rapid assessment of nutritional status in elderly patients in outpatient clinics, hospitals, and nursing homes.
It is composed of simple measurements and brief questions that can be completed in about 10 min
|
Baseline
|
|
Quality of life
Délai: Baseline
|
Quality of life associated with health is going to be measured with two questionnaires: the EuroQol-5 questionnaire and the Health Questionnaire St. George
|
Baseline
|
|
Cough
Délai: Baseline
|
The Leicester Cough Questionnaire-acute is a validated cough-related health status questionnaire designed for patients with chronic cough.
|
Baseline
|
|
Comorbidities
Délai: Baseline
|
Comorbidities are going to be measured with the Charlson comorbidity index.
The Charlson comorbidity index predicts the ten-year mortality for a patient who may have a range of comorbid conditions, such as heart disease, AIDS, or cancer (a total of 22 conditions).
Each condition is assigned a score of 1, 2, 3, or 6, depending on the risk of dying associated with each one.
|
Baseline
|
|
Anxiety and depression
Délai: Baseline
|
Patients are going to completed the Hospital Anxiety and Depression Scale composed of statements relevant to either generalized anxiety or depression.
|
Baseline
|
|
Cognitive flexibility
Délai: Baseline
|
The cognitive flexibility of patients is measured using the Trial Making Test.
This test explores visual-conceptual and visual-motor tracking, and it is a frequently used neuropsychological test.
|
Baseline
|
|
Forced vital capacity
Délai: Baseline
|
Forced vital capacity is going to be measured with a spirometer as recommended by the American Thoracic Society
|
Baseline
|
|
Forced expiratory volume in the first second
Délai: Baseline
|
Forced expiratory volume in the first second is going to be measured with a spirometer as recommended by the American Thoracic Society
|
Baseline
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- DF0051UG
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .